The objective of the panel is to present the benefits of the negotiation committee and the difficulties in the implementation phase, the criteria in decision making and how it will interact with HTA body. Current decision making processes for pharmaceuticals will be described, emphasizing in therapeutic guidelines, reimbursement criteria and functions of negotiation committee. Additionally a proposal of the structure and the criteria of the decision making process of an HTA body will be presented. The proposal was developed by the ISPOR Greece Chapter Board of Directors in an effort to pave the way for the establishment of HTA process which can lead to a sustainable health care system. This forum presentation could be also used as a guide by other CEE countries that are currently in the initiation phase of a Health Technology Assessment organization.